Disease · MONDO_0005387

primary ovarian failure

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. primary ovarian failure. Diseases, record MONDO_0005387. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005387

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: primary ovarian failure; Open Targets
Open Targets ID: MONDO_0005387; Open Targets
Other names: premature ovarian failure, primary ovarian insufficiency, resistant ovary syndrome; Open Targets
Disease Ontology: DOID:5426; Disease Ontology
MeSH: D016649; MeSH
NCI Thesaurus: C113352; NCI Thesaurus
Orphanet: ORPHA:619; Orphanet
Highest stage of its drugs: Approval, for 7 of its 17 drugs, from DailyMed; Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ESTRADIOL	CHEMBL135	Small molecule	Approval	DailyMed	8	3	3	Drugs and targets
FOLLITROPIN	CHEMBL4297955		Approval	DailyMed	5	1	1	Drugs and targets
CHORIOGONADOTROPIN ALFA	CHEMBL1201464	Protein	Approval	DailyMed	3	1	0	Drugs and targets
ESTRADIOL VALERATE	CHEMBL1511	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
ESTROGENS, CONJUGATED	CHEMBL1201649		Approval	DailyMed	1	0	0	Drugs and targets
ESTROGENS, ESTERIFIED	CHEMBL1201468		Approval	DailyMed	1	0	0	Drugs and targets
ESTROPIPATE	CHEMBL1200980	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
TESTOSTERONE	CHEMBL386630	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
GONADORELIN	CHEMBL1007	Protein	Phase 1/2	ClinicalTrials.gov	1	1	0	Drugs and targets
GONADORELIN ACETATE	CHEMBL1200511	Protein	Phase 1/2	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets8

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ESR1	Estrogen receptor	6	Estrogen receptor agonist; Estrogen receptor alpha agonist	Approval	https://conductscience.org/library/genes/2099	Drugs and targets
GNRHR	Gonadotropin-releasing hormone receptor	3	Gonadotropin-releasing hormone receptor agonist	Phase 1/2	https://conductscience.org/library/genes/2798	Drugs and targets
LHCGR	Lutropin-choriogonadotropic hormone receptor	3	Luteinizing hormone/Choriogonadotropin receptor agonist	Approval	https://conductscience.org/library/genes/3973	Drugs and targets
ESR2	Estrogen receptor	2	Estrogen receptor agonist	Approval	https://conductscience.org/library/genes/2100	Drugs and targets
FSHR	Follicle-stimulating hormone receptor	2	Follicle stimulating hormone receptor agonist	Approval	https://conductscience.org/library/genes/2492	Drugs and targets
AR	Androgen receptor	1	Androgen Receptor agonist	Phase 3	https://conductscience.org/library/genes/367	Drugs and targets
NR3C2	Mineralocorticoid receptor	1	Mineralocorticoid receptor antagonist	Unknown	https://conductscience.org/library/genes/4306	Drugs and targets
PGR	Progesterone receptor	1	Progesterone receptor agonist	Unknown	https://conductscience.org/library/genes/5241	Drugs and targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03568708	Primary Ovarian Insufficiency: Phenotype and Optimal Treatment	Phase 3	19	2024-06-25	Primary Ovarian Insufficiency	ESTRADIOL	Its record names the disease	ClinicalTrials.gov
NCT00001951	Hormone Replacement in Young Women With Premature Ovarian Failure	Phase 2	250		Healthy, Osteoporosis, Premature Ovarian Failure	ESTRADIOL, TESTOSTERONE	Its record names the disease	ClinicalTrials.gov
NCT05410093	Clinical Efficacy Analysis of Resveratrol in the Treatment of Primary Ovarian Insufficiency	Not applicable	150		Primary Ovarian Insufficiency	RESVERATROL, VITAMIN E	Its record names the disease	ClinicalTrials.gov
NCT06343870	Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME)	Phase 3	140		Menopause, Testosterone Deficiency, Estrogen Deficiency	ESTRADIOL, TESTOSTERONE	Its record names the disease	ClinicalTrials.gov
NCT04616729	DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation	Phase 1/2	30		Breast Cancer Female	TRIPTORELIN	Its record names the disease	ClinicalTrials.gov
NCT00619333	Inactive FSH in Galactosemia	Not applicable	25		Galactosemia, Premature Ovarian Failure	FOLLITROPIN	Its record names the disease	ClinicalTrials.gov
NCT02757469	Oral Contraceptives as Infertility Treatments for Premature Ovarian Failure	Not applicable	20		Primary Ovarian Insufficiency, Menopause, Premature	DROSPIRENONE, ETHINYL ESTRADIOL	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
POI Participants vs Control Participants: deaths from any cause	0 of 10	0 of 9	19	NCT03568708	Trial comparisons
POI Participants vs Control Participants: serious adverse events	1 of 10	0 of 9	19	NCT03568708	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
24341612	RESULT	1	PubMed
21917867	RESULT	1	PubMed
24905063	DERIVED	1	PubMed
24473536	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005387

GET https://conductscience.org/api/diseases/v1/MONDO_0005387/drugs

API reference For AI assistants